Scientists from Shenzhen Medical Academy of Research and Translation and the Southern Medical University have synthesized solute carrier family 22 member 12 (SLC22A12; URAT1) inhibitors. They are reported to be useful for the treatment of kidney injury, hyperuricemia and gout.
Activating Toll-like receptors (TLRs) with agonists can promote pro-inflammatory responses mediated by the adaptor protein MyD88 and the downstream effector NF-κB, and these responses can inhibit tumor growth.
Cyclin-dependent kinase 9 (CDK9) plays a critical role in regulating transcriptional elongation and is essential for the expression of short-lived oncogenic and antiapoptotic mRNAs. Targeting CDK9 has emerged as a promising therapeutic strategy, particularly in hematological malignancies and MYC-driven cancers. However, its clinical application remains limited by several challenges, which may be overcome through the development of more selective and potent inhibitors.
Toll-like receptor 3 (TLR3) has been noted to impact liver disease and promote liver inflammation. Researchers from Southern Medical University screened a natural product molecular library and found that ellipticine exerted moderate TLR3 inhibitory effects, with an IC50 value of 5.66 µM.
Nephronophthisis (NPH) is a recessive cystic kidney disease responsible for 10% to 20% of pediatric end-stage renal disease cases. NPHP1 (nephrocystin 1) is the most frequently implicated among over 20 known causative genes. However, the pathogenesis of NPH remains unclear, and no effective therapies are available.
Southern Medical University scientists have reported the discovery and preclinical characterization of novel microtubule-inhibiting agents being developed for the treatment of cancer.
Researchers from Southern Medical University and affiliated organizations presented the discovery and preclinical characterization of novel human urate transporter 1 (hURAT1) inhibitors being developed for the treatment of hyperuricemia.
Researchers from Southern Medical University have divulged the discovery and preclinical characterization of novel PDE4 inhibitors for the treatment of hepatic sepsis. Synthesis and optimization of a series of 7-alkoxybenzofurans led to the identification of compound [I] as the lead PDE4 inhibitor, with PDE4B and PDE4D IC50 values of 10.0 and 15.2 nM, respectively.
Researchers from Southern Medical University and affiliated organizations assessed the molecular mechanisms behind TGF-β-induced fibrosis in ovarian endometrioma.
Recent work at Southern Medical University, Guangzhou, focused on the discovery and synthesis of imidazoquinoline-based Toll-like receptor 7 (TLR7) agonists as potential candidates for the treatment of melanoma.
